Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Korea's ViroMed Starts Trial of Gene Therapy for Diabetic Foot Ulcers

publication date: Aug 4, 2017
ViroMed of South Korea has begun dosing patients in a US Phase III trial of VM202, a gene therapy drug, in patients with non-healing diabetic foot ulcers and concomitant peripheral artery disease. Earlier this year, ViroMed filed in China to start a Phase III trial of VM202 in patients with critical limb ischemia, an advanced state of peripheral artery disease. When injected into muscles, VM202 is intended to induce new microvasculature and alleviate a number of conditions associated with diabetes and loss of peripheral arteries. More details....

Stock Symbol: (KOSDAQ: 084990)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here